Null and Noteworthy: Registered reports; motor measurements; viral DNA | Spectrum | Autism Research News
In this edition of Null and Noteworthy, Spectrum talks with a Nature editor about the journal’s move to publish more null results.
Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion | Spectrum | Autism Research News
In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.
Null & Noteworthy: Intervention flops; neural noise; gender care | Spectrum | Autism Research News
This edition takes aim at the autism-intervention evidence base with a slew of null results, plus findings that challenge a prevailing autism brain theory.
Null and Noteworthy: Reinforcing rigor; medication medley | Spectrum | Autism Research News
This month’s newsletter highlights findings on the use of three medication types during pregnancy.
Null and Noteworthy: Brain aging, oxytocin pathways, biomarker back-up | Spectrum | Autism Research News
Null and replicated results in this month’s newsletter tackle aging, a purported pathway for oxytocin’s effects on autistic people, and a possible autism biomarker.
Autism News International